MA37317A1 - Formulation d'anticorps il-17 - Google Patents
Formulation d'anticorps il-17Info
- Publication number
- MA37317A1 MA37317A1 MA37317A MA37317A MA37317A1 MA 37317 A1 MA37317 A1 MA 37317A1 MA 37317 A MA37317 A MA 37317A MA 37317 A MA37317 A MA 37317A MA 37317 A1 MA37317 A1 MA 37317A1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody formulation
- stabilized
- polysorbate
- psoriasis
- citrate
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques stabilisées pour anticorps anti-il -17, comprenant par exemple du citrate, du chlorure de sodium et du polysorbate -80 à un ph de 5,7. Ces formulations pharmaceutiques stabilisées pour anticorps anti-il -17 peuvent être utilisées pour traiter l'arthrite rhumatoïde, le psoriasis, la spondylite ankylosante, l'arthrite psoriasique ou le myélome multiple.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607671P | 2012-03-07 | 2012-03-07 | |
| PCT/US2013/028516 WO2013134052A1 (fr) | 2012-03-07 | 2013-03-01 | Formulation d'anticorps il-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37317A1 true MA37317A1 (fr) | 2016-03-31 |
| MA37317B1 MA37317B1 (fr) | 2016-10-31 |
Family
ID=47892018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37317A MA37317B1 (fr) | 2012-03-07 | 2014-09-02 | Formulation d'anticorps il-17 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9376491B2 (fr) |
| EP (2) | EP3156073A1 (fr) |
| JP (1) | JP6117252B2 (fr) |
| KR (1) | KR101653082B1 (fr) |
| CN (1) | CN104159612B (fr) |
| AU (1) | AU2013230490B2 (fr) |
| BR (1) | BR112014021308B1 (fr) |
| CA (1) | CA2866128C (fr) |
| CL (1) | CL2014002204A1 (fr) |
| CY (1) | CY1118393T1 (fr) |
| DK (1) | DK2822590T3 (fr) |
| EA (1) | EA030742B1 (fr) |
| EC (1) | ECSP14017562A (fr) |
| ES (1) | ES2610707T3 (fr) |
| HR (1) | HRP20161604T1 (fr) |
| HU (1) | HUE031290T2 (fr) |
| IL (1) | IL234053B (fr) |
| LT (1) | LT2822590T (fr) |
| MA (1) | MA37317B1 (fr) |
| ME (1) | ME02565B (fr) |
| MX (1) | MX362191B (fr) |
| MY (1) | MY167233A (fr) |
| NZ (1) | NZ627648A (fr) |
| PE (1) | PE20142275A1 (fr) |
| PH (1) | PH12014501985A1 (fr) |
| PL (1) | PL2822590T3 (fr) |
| PT (1) | PT2822590T (fr) |
| RS (1) | RS55417B1 (fr) |
| SG (1) | SG11201404491XA (fr) |
| SI (1) | SI2822590T1 (fr) |
| TN (1) | TN2014000341A1 (fr) |
| UA (1) | UA114620C2 (fr) |
| WO (1) | WO2013134052A1 (fr) |
| ZA (1) | ZA201405654B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2018211517A1 (fr) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | Formulations de protéines à haute concentration ayant une viscosité réduite |
| WO2019027828A1 (fr) | 2017-08-04 | 2019-02-07 | Eli Lilly And Company | Schéma posologique d'anticorps anti-il-17 |
| WO2019040230A1 (fr) | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | Traitement du psoriasis génital |
| MX2017016884A (es) * | 2017-12-19 | 2019-06-20 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina anti-tnfa. |
| KR20210096640A (ko) * | 2018-11-29 | 2021-08-05 | 하버 바이오메드 테라푸틱스 리미티드 | 항-pd-l1 항체 제제 |
| PH12021551916A1 (en) | 2019-02-18 | 2022-05-23 | Lilly Co Eli | Therapeutic antibody formulation. |
| WO2022135395A1 (fr) * | 2020-12-22 | 2022-06-30 | 百奥泰生物制药股份有限公司 | Préparation d'anticorps stable, son procédé de préparation et ses applications |
| CN119147687B (zh) * | 2024-11-11 | 2025-03-14 | 智翔（上海）医药科技有限公司 | 用于抗白介素17a抗体质量检测的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3366702B1 (fr) * | 2005-12-13 | 2023-08-09 | Eli Lilly And Company | Anticorps anti-il-17 |
| WO2008068246A1 (fr) * | 2006-12-05 | 2008-06-12 | Crucell Holland B.V. | Formulations liquides d'anticorps anti-rage |
| ES2753216T3 (es) * | 2010-01-15 | 2020-04-07 | Amgen K A Inc | Formulación de anticuerpos anti-IL17RA y regímenes terapéuticos para el tratamiento de la psoriasis |
-
2013
- 2013-03-01 DK DK13710214.1T patent/DK2822590T3/en active
- 2013-03-01 JP JP2014560955A patent/JP6117252B2/ja active Active
- 2013-03-01 BR BR112014021308-9A patent/BR112014021308B1/pt active IP Right Grant
- 2013-03-01 ES ES13710214.1T patent/ES2610707T3/es active Active
- 2013-03-01 LT LTEP13710214.1T patent/LT2822590T/lt unknown
- 2013-03-01 HU HUE13710214A patent/HUE031290T2/hu unknown
- 2013-03-01 PT PT137102141T patent/PT2822590T/pt unknown
- 2013-03-01 ME MEP-2016-259A patent/ME02565B/fr unknown
- 2013-03-01 EP EP16195503.4A patent/EP3156073A1/fr not_active Withdrawn
- 2013-03-01 WO PCT/US2013/028516 patent/WO2013134052A1/fr not_active Ceased
- 2013-03-01 AU AU2013230490A patent/AU2013230490B2/en active Active
- 2013-03-01 CN CN201380012452.5A patent/CN104159612B/zh active Active
- 2013-03-01 MY MYPI2014702489A patent/MY167233A/en unknown
- 2013-03-01 US US14/379,755 patent/US9376491B2/en active Active
- 2013-03-01 PE PE2014001367A patent/PE20142275A1/es active IP Right Grant
- 2013-03-01 MX MX2014010710A patent/MX362191B/es active IP Right Grant
- 2013-03-01 CA CA2866128A patent/CA2866128C/fr active Active
- 2013-03-01 KR KR1020147024733A patent/KR101653082B1/ko active Active
- 2013-03-01 UA UAA201409450A patent/UA114620C2/uk unknown
- 2013-03-01 EP EP13710214.1A patent/EP2822590B1/fr active Active
- 2013-03-01 SG SG11201404491XA patent/SG11201404491XA/en unknown
- 2013-03-01 SI SI201330364A patent/SI2822590T1/sl unknown
- 2013-03-01 EA EA201491471A patent/EA030742B1/ru not_active IP Right Cessation
- 2013-03-01 HR HRP20161604TT patent/HRP20161604T1/hr unknown
- 2013-03-01 RS RS20160994A patent/RS55417B1/sr unknown
- 2013-03-01 PL PL13710214T patent/PL2822590T3/pl unknown
- 2013-03-01 NZ NZ627648A patent/NZ627648A/en unknown
-
2014
- 2014-07-30 ZA ZA2014/05654A patent/ZA201405654B/en unknown
- 2014-08-06 TN TNP2014000341A patent/TN2014000341A1/fr unknown
- 2014-08-11 IL IL234053A patent/IL234053B/en active IP Right Grant
- 2014-08-19 CL CL2014002204A patent/CL2014002204A1/es unknown
- 2014-09-02 MA MA37317A patent/MA37317B1/fr unknown
- 2014-09-05 PH PH12014501985A patent/PH12014501985A1/en unknown
- 2014-09-05 EC ECIEPI201417562A patent/ECSP14017562A/es unknown
-
2016
- 2016-06-10 US US15/178,583 patent/US9845353B2/en active Active
- 2016-12-23 CY CY20161101339T patent/CY1118393T1/el unknown
-
2017
- 2017-11-10 US US15/808,939 patent/US10472416B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37317B1 (fr) | Formulation d'anticorps il-17 | |
| MA44312A (fr) | Anticorps et leurs méthodes d'utilisation | |
| MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA51747A (fr) | Formulation d'anticorps pharmaceutique à ph faible | |
| MA40035A (fr) | Molécules d'anticorps de pd-l1 et leurs utilisations | |
| MA44659B1 (fr) | Anticorps anti-tim-3 et compositions | |
| MA38194B1 (fr) | Anticorps anti-ceacam5 et leurs utilisations | |
| MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| MA31437B1 (fr) | Polypeptides, domaines variables d'anticorps et antagonistes | |
| MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| MA41072A1 (fr) | Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| MA38250A1 (fr) | Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie | |
| MA34487B1 (fr) | Compositions d'anticorps anti-vegfr-3. | |
| MA38699A1 (fr) | Formulation orale pour le traitement de maladies cardiovasculaires | |
| MA46778B1 (fr) | Composition intranasale comprenant de la bétahistine | |
| MA20150424A1 (fr) | Compositions liquides orales pédiatriques contenant du nepadutant | |
| EP4165078A4 (fr) | Dosage d'anticorps neutralisants contre le polyomavirus |